ERIPIRA SYRUP – Piracetam 500mg/5ml Oral Solution
The clinical case for a Piracetam syrup rests on who cannot swallow a tablet. Post-stroke dysphagia is common in exactly the patient group Piracetam is prescribed for, and the same applies to advanced dementia, post-head-injury recovery and paediatric neurological cases. In these patients a syrup is not a convenience format — it is often the only administrable one, including through a nasogastric tube where required.
Product Specifications
Brand Name: ERIPIRA SYRUP
Composition: Each 5 ml contains Piracetam IP 500 mg in a flavoured syrup base
Dosage Form: Oral Solution (Syrup)
Therapeutic Category: Neuropsychiatry, CNS, Neuroprotectives
Manufacturing: WHO-GMP certified facility
Prescription Status: Schedule H
Storage: Store below 25°C, protect from light. Do not freeze.
Composition
Piracetam IP — 500 mg per 5 ml — Nootropic agent; influences neuronal membrane fluidity and cholinergic neurotransmission
Flavoured Syrup Base — q.s.
Mechanism of Action
Piracetam acts on the physical properties of neuronal membranes rather than on a specific receptor. By improving membrane fluidity, it influences the behaviour of receptors and neurotransmitter systems embedded in those membranes, with particular relevance to cholinergic transmission underlying memory and cognition. It has additionally been associated with effects on erythrocyte deformability and cerebral microcirculation, which is relevant where perfusion is compromised, as in cerebrovascular insufficiency and post-ischemic states.
Delivered as an oral solution, absorption is not dependent on tablet disintegration, which supports more predictable administration in patients with impaired swallowing or altered gastric transit.
Clinical Applications
- Post-stroke cognitive recovery, particularly where dysphagia limits solid dosage forms
- Cognitive impairment associated with cerebrovascular insufficiency
- Traumatic brain injury and post-head-injury recovery
- Myoclonus of cortical origin, as prescribed
- Age-related cognitive decline in patients unable to take tablets
- Paediatric neurological indications, on specialist assessment
- Vertigo of central origin
Administration Advantages of the Syrup Form
Dose titration in millilitres allows finer adjustment than fixed-strength tablets, which matters in paediatric dosing calculated by body weight and in elderly patients requiring gradual escalation. The liquid form is also administrable via nasogastric tube where a patient cannot take medication orally at all — a route unavailable to solid formats without compounding.
Prescriber Profile
Neurologists form the primary prescribing base, particularly in post-stroke and post-head-injury protocols where swallowing is impaired. Neurosurgeons prescribe it in post-operative neurological recovery. Paediatric neurologists account for use in childhood neurological presentations, and geriatricians and physicians for cognitive decline in patients unable to manage tablets.
Dosage and Administration
As prescribed by a Registered Medical Practitioner, with the dose measured using the calibrated measure supplied. Shake before use. This is a Schedule H drug — sale by retail is permitted only against the prescription of a Registered Medical Practitioner.
Safety Information
Dose adjustment is required in renal impairment, as Piracetam undergoes renal clearance — relevant in elderly patients, in whom renal function is frequently reduced. Treatment should not be discontinued abruptly in patients on long-term therapy without physician guidance. Not indicated in known hypersensitivity to Piracetam. Store below 25°C, protect from light, and use within the period specified after opening. Keep out of reach of children.
Range Positioning
ERIPIRA SYRUP extends the Piracetam range alongside ERIPIRA-C PLUS, the Citicoline 500mg and Piracetam 800mg tablet. A prescriber managing a post-stroke patient can start on syrup during the dysphagic phase and transition to the tablet as swallowing recovers, without the prescription moving to another company at the point of switch.
PCD Pharma Franchise Availability
ERIPIRA SYRUP is available for PCD Pharma Franchise across India. Territory rights are allotted on a monopoly basis subject to availability, and franchise partners receive promotional inputs and product literature across the neuropsychiatry and CNS range.
Frequently Asked Questions
Why is Piracetam supplied as a syrup when tablets are available?
Post-stroke dysphagia is common in the patient group Piracetam is prescribed for, as is impaired swallowing in advanced dementia and post-head-injury recovery. A syrup is administrable in these patients, including via nasogastric tube, where tablets are not.
How is the dose measured?
Using the calibrated measure supplied, in millilitres, which allows finer titration than fixed-strength tablets — relevant in weight-based paediatric dosing and in gradual escalation in elderly patients.
Does ERIPIRA SYRUP require dose adjustment in any patient group?
Yes, in renal impairment, since Piracetam is cleared renally. This is determined by the prescribing physician and is particularly relevant in elderly patients.
How does ERIPIRA SYRUP relate to ERIPIRA-C PLUS?
ERIPIRA-C PLUS is a Citicoline 500mg and Piracetam 800mg tablet. ERIPIRA SYRUP provides Piracetam alone in liquid form, allowing a patient to be started on syrup and transitioned to tablet as swallowing recovers.
Is ERIPIRA SYRUP available for PCD Pharma Franchise in India?
Yes. ERIPIRA SYRUP is available for PCD Pharma Franchise across India under Eridanus Healthcare, with monopoly-basis territory rights subject to availability.
Which prescribers form the target base for Piracetam syrup in a PCD Pharma Franchise range?
Neurologists and neurosurgeons are the primary prescribers, with paediatric neurologists, geriatricians and physicians as secondary coverage — relevant for franchise partners building a neuropsychiatry and CNS portfolio.
Why should a distributor stock a syrup form alongside tablets?
Most competing neuro ranges carry tablets only, which means a prescriber treating a dysphagic patient has to look elsewhere. Carrying the syrup keeps that prescription within the same range rather than sending it to a competitor at the point of need.
How can a distributor apply for PCD Pharma Franchise rights for ERIPIRA SYRUP?
Distributors and pharmaceutical professionals holding a valid Drug Licence and GST registration may contact Eridanus Healthcare to discuss territory availability and franchise terms.
This page is intended for pharmaceutical distributors, wholesalers, and healthcare professionals. Product information is provided for commercial and educational reference and is not a substitute for professional medical advice. Eridanus Healthcare does not sell directly to patients. This is a Schedule H drug — to be sold by retail only on the prescription of a Registered Medical Practitioner. All trade enquiries are subject to valid Drug Licence and GST verification.